Left Atrial Appendage Thrombus Formation Despite Continuous Non-Vitamin K Antagonist Oral Anticoagulant Therapy in Atrial Fibrillation Patients Undergoing Electrical Cardioversion or Catheter Ablation: A Comparison of Dabigatran and Rivaroxaban

Table 4

Univariate and multivariate analysis of predictive factors for LAAT in patients treated with dabigatran.

Variable	Univariate analysis			Multivariate analysis
	OR	95% CI		OR	95% CI
Heart failure	4.55	2.16–9.6	0.0001	3.22	1.50–6.95	0.003
Hypertension	1.04	0.45–2.38	0.93
Age (per 5 years)	1.40	1.15–1.70	0.0009
Diabetes mellitus	2.90	1.36–6.21	0.006
Stroke/TIA/peripheral thrombus	1.22	0.36–4.15	0.7558
Vascular disease	1.93	0.88–4.23	0.1015
Female	1.86	0.89–3.89	0.097
Non-paroxysmal AF	9.18	2.17–3.89	0.0026	6.20	1.43–26.93	0.015
eGFR < 60 ml/min/1.73 m^2	2.98	1.42–6.24	0.0039	2.65	1.24–5.66	0.012

95% CI, 95% confidence interval; AF, atrial fibrillation; eGFR, estimated glomerular filtration rate; OR, odds ratio; TIA, transient ischaemic attack.